Not yet recruiting
B precursor type acute leukaemia
Not yet recruitingPhase II study of autologous enriched T‑cell therapy expressing CD19 and CD22 CARs in Philadelphia‑negative B‑precursor ALL patients with measurable residual disease
InvestigationalNo placebo
Phase II study of autologous enriched T‑cell therapy expressing CD19 and CD22 CARs in Philadelphia‑negative B‑precursor ALL patients with measurable residual disease
InvestigationalNo placebo
- Disease:B precursor type acute leukaemia
- Substances:Autologous Enriched T Cells Retrovirally Transduced To Express Two Chimeric Antigen Receptors Targeting Cd19 And Cd22
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Autologous Enriched T Cells Retrovirally Transduced To Express Two Chimeric Antigen Receptors Targeting Cd19 And Cd22